Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-B cell lymphoma BCL1 Idiotype antibody variable domains fused with a scFv from an anti-CD3 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can block cell adhesion. It is designed for the research of B cell lymphoma therapy.